Author

D. Helm

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:proteomics· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

M. Schneider· 3 shared M. Rettel· 2 shared A. A. Martija· 1 shared A. Christians· 1 shared A. E. Kulozik· 1 shared A. Ertl· 1 shared A. Hernandez-Sanchez· 1 shared A. Krauss· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Schneider

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A multi-year longitudinal harmonization of quality controls in mass spectrometry proteomics core facilities

C. Chiva, R. Olivella, A. Staes, T. M. Maia, C. Panse, K. Stejskal, T. Douche, B. Lombard, A. Schuhmann, D. Loew, K. Mechtler, M. Matondo, M. Rettel, D. Helm, F. Impens, , E. Sabido

This study harmonizes quality controls across proteomics core facilities to improve data comparability and reliability through a 4-year longitudinal dataset and common processing software.

bioRxiv · May 19, 2024 · PreprintBiochemistry

EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma

A. A. Martija, A. Krauss, N. Baechle, L. Doth, A. Christians, D. Krunic, M. Schneider, D. Helm, R. Will, C. Hartmann, C. Herold-Mende, A. von Deimling, S. Pusch

This study identifies EMP3 as a regulator of EGFR/CDK2 signaling in glioblastoma by stabilizing EGFR and promoting its oncogenic activity.

bioRxiv · May 6, 2023Cancer Biology

A multidimensional atlas of human glioblastoma organoids reveals highly coordinated molecular networks and effective drugs

C. Wang, M. Sun, C. Shao, L. Schlicker, Y. Zhuo, Y. Harim, T. Peng, W. Tian, N. stoeffler, M. Schneider, D. Helm, J.-P. Mallm, Y. Wu, A. Schulze, H.-K. LIU

This study characterizes human glioblastoma organoids using multi-omics analysis and identifies drug targets linked to glycerol lipid reprogramming.

bioRxiv · Jan 24, 2023 · PreprintCancer Biology

IRON REGULATORY PROTEIN (IRP)-MEDIATED IRON HOMEOSTASIS IS CRITICAL FOR NEUTROPHIL DEVELOPMENT AND DIFFERENTIATION IN THE BONE MARROW

M. Bonadonna, S. Altamura, E. Tybl, G. Palais, M. Qatato, M. Polycarpou-Schwarz, M. Schneider, C. Kalk, W. Ruediger, A. Ertl, N. Anstee, R. Bogeska, D. Helm, M. D. Milsom, B. Galy

This study shows that IRP-mediated iron homeostasis is essential for neutrophil development and differentiation in the bone marrow, with no effect on monocyte counts.

bioRxiv · Mar 16, 2022Immunology

Pharmacological inhibition of nonsense-mediated RNA decay augments HLA class I-mediated presentation of neoepitopes in MSI CRC

J. P. Becker, D. Helm, M. Rettel, F. Stein, A. Hernandez-Sanchez, K. Urban, J. Gebert, M. Kloor, G. Neu-Yilik, M. von Knebel Doeberitz, M. W. Hentze, A. E. Kulozik

The paper shows that inhibiting nonsense-mediated RNA decay increases HLA class I presentation of neoepitopes from frameshift mutations in MSI colorectal cancer.

bioRxiv · Oct 13, 2020Cancer Biology